Thus, targeting the SNHG16/miR‐605‐3p/TRAF6/NF‐κB loop may be a potential new therapeutic strategy to improve the treatment and survival of HCC patients (Figure 7J). This evidence concerns the gene TRAF6 and hepatocellular carcinoma.